Compare Expedia Group Inc (EXPE) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Gilead Sciences, Inc. — how do they compare? Expedia Group Inc trades at $269.5 (market cap $32.42B), while Gilead Sciences, Inc. trades at $147 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 5.6× Expedia Group Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and Gilead Sciences, Inc. for 111 Days on average.
| EXPE | GILD | |
|---|---|---|
Market Cap | $32.42B | $182.40B |
Volume | 1,940,671 | 4,469,821 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $155.80 |
52-Week Low | $188.51 | $116.74 |
Typical Hold Time | 48 Days | 111 Days |
Enterprise Value | $30.98B | $205.46B |
Dividend Yield | 0.71% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, with technical indicators showing bearish momentum as the stock tests key support levels. Fundamentally, the company demonstrates strong revenue growth from $14.73B in 2025 to projected $15.7B in 2026, with net income margins improving to 12.97%. Recent earnings beats and a 47.37% analyst buy rating support the positive outlook, though competition from AI travel agents presents headwinds.
The stock offers significant upside to the $335.06 consensus price target, representing 29% potential appreciation. Strong cash flow generation and improving profitability metrics support the bullish case, but investors must monitor competitive threats from AI disruption and recent layoffs indicating operational challenges. The current valuation at 16.28 P/E appears reasonable given growth prospects.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
